Cargando…

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948

PURPOSE: [(18)F]flortaucipir binds to paired helical filament tau and accurately identifies tau in Alzheimer’s disease (AD). However, “off-target” binding interferes with the quantification of [(18)F]flortaucipir in several brain regions. Recently, other tau PET tracers have been developed. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Ruben, Schöll, Michael, Leuzy, Antoine, Jögi, Jonas, Ohlsson, Tomas, Strandberg, Olof, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974501/ https://www.ncbi.nlm.nih.gov/pubmed/31612245 http://dx.doi.org/10.1007/s00259-019-04496-0

Ejemplares similares

A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2021)

[(18)F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
por: Santillo, Alexander F., et al.
Publicado: (2022)

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
por: Leuzy, Antoine, et al.
Publicado: (2020)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [(18)F]flortaucipir study
por: O’Connor, Antoinette, et al.
Publicado: (2023)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [(18)F]Flortaucipir PET
por: Risacher, Shannon L., et al.
Publicado: (2018)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
por: Smith, Ruben, et al.
Publicado: (2020)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

Machine learning application for classification of Alzheimer's disease stages using (18)F-flortaucipir positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
por: Tian, Mei, et al.
Publicado: (2022)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Comparison of New Tau PET-Tracer Candidates With [(18)F]T808 and [(18)F]T807
por: Declercq, Lieven, et al.
Publicado: (2016)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Association of the top 20 Alzheimer's disease risk genes with [(18)F]flortaucipir PET
por: Stage, Eddie, et al.
Publicado: (2022)

Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation
por: Wright, Justin P., et al.
Publicado: (2022)

Image reconstruction methods affect software-aided assessment of pathologies of [(18)F]flutemetamol and [(18)F]FDG brain-PET examinations in patients with neurodegenerative diseases
por: Lindström, Elin, et al.
Publicado: (2020)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Uptake of [(18)F] EF5 as a Tracer for Hypoxic and Aggressive Phenotype in Experimental Head and Neck Squamous Cell Carcinoma()
por: Silén, Jonna, et al.
Publicado: (2014)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Ultrafast Photoclick Reaction for Selective (18)F-Positron Emission Tomography Tracer Synthesis in Flow
por: Fu, Youxin, et al.
Publicado: (2021)

Head-to-head comparison of [(18)F]-fluorodeoxyglucose and [(18)F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series
por: Thientunyakit, Tanyaluck, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cd8k0io1kqsmgkn6s1kkiovpvu